Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic melanoma. Another purpose of this study is to determine the effect of ipilimumab, nivolumab and hypofractionated radiotherapy on the cancer as compared to ipilimumab and nivolumab.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
Primary purpose
Allocation
Interventional model
Masking
52 participants in 2 patient groups
Loading...
Central trial contact
Tara Mitchell, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal